«-pentyl-DvFc (2.5 jug/ml) whereas no-drug control cells showed 81% positive on the third day after infection (Fig. 2) . However, the MT-4 cell line is one of the HTLV-I-transformed cell lines which have been known to be highly sensitive to cytotoxicity of «-pentyl-DvFc2). In fact, MT-4 cells seemed to be almost in a static state under this condition (2. 5 Aig/ml).
Thus, we examined the anti-HIV effect of «-pentyl-DvFc using the HTLV-I-negative cell lines, H-9, HUT-78 or U937 as permissive host cells of HIV. In these cells, the 50% cytotoxic dose (CD50) of«-pentyl-DvFc was in the range of9 jug/ml (U937) to 16^g/ml (HUT-78), and was higher than that of MT-4 cells (2 jug/ml).
«-Pentyl-DvFc suppressed the expression of HIV-antigen in dose dependent manner in these three cell lines (Fig. 3) . About 50% inhibition (ED50) was observed at a concentration of 3^g/ml. 3'-Azido-3'-deoxythymidine (AZT), used as a positive control, showed ED50 values ranging from 0.013 jig/ml (H-9) to 0.024/ig/ml (HUT-78). The mechanism of the inhibitory effect of «-pentyl-DvFc on HIVreplication is not clear at the present moment. Selective efficacy (ratio of CD50 to ED50) of H-pentyl-DvFc was in the range of about 3 to 5 in these three cell lines, suggesting that this drug acts on the host cell metabolism rather than on the virus itself. MT-4cells were infected with HIV at a multiplicity of infection of 0.006 and incubated in the absence (à") or presence (O 1 /xg/ml, A 2.5 //g/ml) ofH-pentyl-DvFc. For the expression of HIV-specific antigens, indirect immunofluorescence was done. H-9, HUT-78, or U937 cells were infected with HIV and incubated in the presence of w-pentyl-DvFc. After 6 days, cells were subjected to immunofluorescence.
Although the HIV-specificity is low as compared to that of HIV-selective inhibitors including AZT, «-pentyl-DvFc might be useful for the therapy of HIV-infected diseases in combination with anti-HIV drugs.
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